{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:46:18Z","timestamp":1785228378156,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.acuro.2017.10.003","type":"journal-article","created":{"date-parts":[[2017,12,30]],"date-time":"2017-12-30T08:08:41Z","timestamp":1514621321000},"page":"238-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Eficacia y seguridad de distintas cepas de BCG en el tratamiento del tumor vesical en pr\u00e1ctica cl\u00ednica habitual"],"prefix":"10.1016","volume":"42","author":[{"given":"M.","family":"Unda-Urzaiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Cozar-Olmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mi\u00f1ana-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Camarero-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Brugarolas-Rossello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zubiaur-Libano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Ribal-Caparros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Suarez-Charneco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rodriguez-Tesedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chantada-Abal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ruiz-de-Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Carrillo-George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carballido-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Villacampa-Auba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2017.10.003_bib0125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/oxfordjournals.epirev.a036234","article-title":"Bladder cancer epidemiology","volume":"3","author":"Matanoski","year":"1981","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.acuro.2017.10.003_bib0130","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0213-9111(01)71591-9","article-title":"Cancer incidence estimation in Spain: Period 1993-1996","volume":"15","author":"Moreno","year":"2001","journal-title":"Gac Sanit"},{"key":"10.1016\/j.acuro.2017.10.003_bib0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0140","unstructured":"Gu\u00eda de la Asociaci\u00f3n Europea de Urolog\u00eda. Non-muscle-invasive Bladder Cancer [consultado 14 Sep 2017]. Disponible en: http:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/"},{"key":"10.1016\/j.acuro.2017.10.003_bib0145","unstructured":"Gu\u00eda de la Asociaci\u00f3n Americana de Urolog\u00eda. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer [consultado 14 Sep 2017]. Disponible en: https:\/\/www.auanet.org\/guidelines\/non-muscle-invasive-bladder-cancer-aua\/suo-joint-guideline-2016"},{"key":"10.1016\/j.acuro.2017.10.003_bib0150","unstructured":"Gu\u00eda de la NCCN. Bladder cancer [consultado 14 Sep 2017]. Disponible en: https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp"},{"key":"10.1016\/j.acuro.2017.10.003_bib0155","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.acuro.2013.04.002","article-title":"Tratamiento del tumor vesical no m\u00fasculo infiltrante frente al problema de disponibilidad de bacilo de Calmette-Guerin. Consenso de un panel de expertos espa\u00f1oles","volume":"37","author":"Fern\u00e1ndez-G\u00f3mez","year":"2013","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2017.10.003_bib0160","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: Multivariate analysis of data from four randomized CUETO trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0165","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model","volume":"182","author":"Fernandez","year":"2009","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1473-3099(02)00182-2","article-title":"BCG\u2014different strains, different vaccines?","volume":"2","author":"Behr","year":"2002","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.acuro.2017.10.003_bib0175","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian strains showed the highest direct antitumor effects of different bacillus Calmette-Gu\u00e9rin substrains","volume":"189","author":"Secanello-Fandos","year":"2012","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Guerin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0974-7796.106873","article-title":"Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guerin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison","volume":"5","author":"Inamoto","year":"2013","journal-title":"Urol Ann."},{"key":"10.1016\/j.acuro.2017.10.003_bib0190","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-5347(01)67606-7","article-title":"A randomized study of intravesical mitomycinC, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder","volume":"153","author":"Vegt","year":"1995","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1569-9056(07)60152-3","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) used for intravesical instillations in the treatment of nonmuscle invasive transitional cell carcinoma (TCC) of the bladder: Does the strain matter?","volume":"6","author":"Thalmann","year":"2007","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2017.10.003_bib0200","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.1016\/S1569-9056(12)60959-2","article-title":"The BCG strain used is relevant for recurrence-free survival: A randomized phaseIII study comparing Immucyst\u00ae versus Oncotice\u00ae","volume":"11","author":"Birkhauser","year":"2012","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2017.10.003_bib0205","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rendtsch","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0210","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer \u2014 the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat Rev Urol."},{"key":"10.1016\/j.acuro.2017.10.003_bib0215","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1016\/S1569-9056(15)60936-8","article-title":"The impact of different BCG strains on outcome in a large cohort of T1G3 patients treated with BCG","volume":"14","author":"Pisano","year":"2015","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuro.2017.10.003_bib0220","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.acuro.2017.03.003","article-title":"Tratamiento adyuvante intravesical en c\u00e1ncer de vejiga no m\u00fasculo invasivo: Importancia de la cepa y el mantenimiento","volume":"41","author":"Guerrero-Ramos","year":"2017","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2017.10.003_bib0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/47042","article-title":"Complex lipids determines tissue-specific replication of Mycobacterium tuberculosis in mice","volume":"402","author":"Cox","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.acuro.2017.10.003_bib0230","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1586\/14737140.1.4.531","article-title":"Gene therapy for superficial bladder cancer","volume":"1","author":"Rosser","year":"2001","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.1016\/j.acuro.2017.10.003_bib0235","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1586\/14760584.2015.1068124","article-title":"Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy","volume":"14","author":"Zheng","year":"2015","journal-title":"Expert Rev Vaccines."},{"key":"10.1016\/j.acuro.2017.10.003_bib0240","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1016\/j.biomaterials.2013.09.027","article-title":"A magnetic chitosan hydrogel for sustained and prolonged delivery of bacillus Calmette-Gu\u00e9rin in the treatment of bladder cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617302218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617302218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T17:48:18Z","timestamp":1570556898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480617302218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0210480617302218"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2017.10.003","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficacia y seguridad de distintas cepas de BCG en el tratamiento del tumor vesical en pr\u00e1ctica cl\u00ednica habitual","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2017.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}